Sedation Pipeline (8 Companies, 9 Drug Profiles) and Pain Management Market 2015 Research Reports

PUNE, India, September 3, 2015 /PRNewswire/ --

Market research reports titled Sedation - Pipeline Review, H2 2015 and Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain are now available in the pharmaceuticals business intelligence collection of ReportsnReports.com.

Complete report on sedation market pipeline for H2 2015 spread across 61 pages, talking about 8 companies, 9 drug profiles and supported with 24 tables and 12 figures is now available at http://www.reportsnreports.com/reports/419517-sedation-pipeline-review-h2-2015.html .

The Sedation - Pipeline Review, H2 2015 market research report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report provides a snapshot of the global therapeutic landscape of Sedation. It reviews key pipeline products under drug profile section which include product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The research also helps review key players involved in the therapeutics development for Sedation and enlists all their major and minor projects. It summarizes all the dormant and discontinued pipeline projects with a review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Sedation pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are provided.

Companies involved in sedation therapeutics development and covered in this pipeline review report include Advicenne Pharma, AstraZeneca Plc, Concert Pharmaceuticals, Inc., Drawbridge Pharmaceuticals Pty Ltd, Jiangsu Nhwa Pharma Corporation, NanoMedex Pharmaceuticals, Inc., Paion AG and The Medicines Company. Drug profiles covered include ABP-700, ADV-6209, alphaxalone, clonidine hydrochloride, CTP-354, propofol, propofol microemulsion, remimazolam and Small Molecule to Agonize GABA-A for Sedation. Order a copy of Sedation - Pipeline Review, H2 2015 market research report at http://www.reportsnreports.com/Purchase.aspx?name=419517 .

The second research on pain management market titled Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain says globally, pain is one of the important therapy areas with a market size of over $50b in 2013, and is expected to grow at 10%. The patent expiry of Cymbalta and Lyrica (2018) will have significant impact on the overall pain market size in the near future. However, several pipeline molecules are emerging to fill this gap. This report discusses a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence's CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term.

Companies mentioned in the pain management market 2015 research include AbbVie, AcelRx, Acorda Therapeutics, Actavis, Acura Pharma, Altus formulations, Amorsa Therapeutics, AstraZeneca, BioDelivery Sciences International Inc, Cara Therapeutics, Catalent, Charleston, Collegium Pharma, Convergence, Daiichi, Daewoong, Depomed, Durect, Egalet, Eli Lilly, Elite Pharma, Endo, Flamel Technologies, Flexion Therapeutics, Glenmark, Grunenthal, Immune Pharmaceuticals, Impax Pharmaceuticals, Inspirion Delivery technologies, Intelli Pharmaceutics, Johnson and Johnson, KemPharm, Kineta, Kunwha Pharmaceutical, Medallion Therapeutics, Nektar, Orbis Biosciences, Orexo, Pain Therapeutics, Pfizer, Purdue, Recro, Relmada Therapeutics, Signature Therapeutics, Spinifex pharma, SPR Therapeutics, Teikoku, Teva, Trevena Inc, Tris Pharma, Valeant, Xenon Pharma and XenoPort. Comprehensive table of contents and more on this research is available at http://www.reportsnreports.com/reports/323781-therapeutic-class-overview-moderate-to-severe-pain-novel-abuse-deterrent-formulation-technologies-and-emergence-of-novel-mechanisms-in-the-management-of-pain.html .

Explore more reports, newly published as well as relevant research titles, on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com